Skip to main content
Top
Published in: Diabetes Therapy 1/2020

Open Access 01-01-2020 | Type 1 Diabetes | Original Research

The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies

Authors: Mark Evans, Zoë Welsh, Sara Ells, Alexander Seibold

Published in: Diabetes Therapy | Issue 1/2020

Login to get access

Abstract

Introduction

Glycated haemoglobin A1c (HbA1c) is the established standard measurement for assessment of glycaemic control in people with diabetes. Here we report on a meta-analysis of real-world observational studies on the impact of flash continuous glucose monitoring on glycaemic control as measured by HbA1c.

Methods

A total of 271 studies were identified in our search, of which 29 contained data reporting changes in HbA1c over periods from 1 to 24 months that could be used in a statistical analysis. Our meta-analysis focuses on observed change in HbA1c at either 2, 3 or 4 months, in adult or paediatric subjects, as well as a longitudinal analysis up to 12 months in adult subjects. These data were drawn from 25 of the studies identified in our initial search. These reported HbA1c data up to 12 months in a total of 1723 participants with type 1 diabetes (T1D) or type 2 diabetes (T2D) using the FreeStyle Libre® flash glucose monitoring system.

Results

Overall mean change in laboratory HbA1c across study subjects at 2–4 months was − 0.55% (95% CI − 0.70, − 0.39). Amongst the 1023 adults, mean change in HbA1c was − 0.56% (95% CI − 0.76, − 0.36); for the 447 children and adolescents, mean change in HbA1c was − 0.54% (95% CI − 0.84, − 0.23). Based on regression analysis, the degree of change in HbA1c correlated with the initial HbA1c of the study population. A longitudinal analysis in adult subjects (n = 1276) shows that HbA1c fell within the first 2 months and changes were sustained up to 12 months. No significant differences were detected between T1D and T2D.

Conclusion

The meta-analysis reported here confirms that starting the FreeStyle Libre system as part of diabetes care results in a significant and sustained reduction in HbA1c for adults and children with T1D and for adults with T2D.

Funding

Abbott Diabetes Care.
Literature
1.
go back to reference The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.CrossRef
2.
go back to reference UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.CrossRef
3.
go back to reference Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRef Holman RR, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–89.CrossRef
4.
go back to reference The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76.CrossRef The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008;359:1464–76.CrossRef
5.
go back to reference Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections. The DIAMOND randomized clinical trial. JAMA. 2017;317:371–8.CrossRef Beck RW, Riddlesworth T, Ruedy K, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections. The DIAMOND randomized clinical trial. JAMA. 2017;317:371–8.CrossRef
6.
go back to reference Beck RW, Riddlesworth T, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365–74.CrossRef Beck RW, Riddlesworth T, Ruedy K, et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: a randomized trial. Ann Intern Med. 2017;167:365–74.CrossRef
7.
go back to reference Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial JAMA. 2017;317:379–87.CrossRef Lind M, Polonsky W, Hirsch IB, et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: the GOLD randomized clinical trial JAMA. 2017;317:379–87.CrossRef
8.
go back to reference Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155–62.CrossRef Battelino T, Conget I, Olsen B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia. 2012;55:3155–62.CrossRef
10.
go back to reference Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–63.CrossRef Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–63.CrossRef
11.
go back to reference Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.CrossRef Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.CrossRef
12.
go back to reference Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283:2008–12.CrossRef Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA. 2000;283:2008–12.CrossRef
13.
go back to reference von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495–9.CrossRef von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Int J Surg. 2014;12:1495–9.CrossRef
14.
go back to reference Gibb FW, Stimson RH, Zammitt NN, et al. Flash glucose monitoring is associated with improved glycaemic control and quality of life in people with type 1 diabetes: a large ‘real-world’ assessment. Diabetologia. 2018;16(S1):S391. Gibb FW, Stimson RH, Zammitt NN, et al. Flash glucose monitoring is associated with improved glycaemic control and quality of life in people with type 1 diabetes: a large ‘real-world’ assessment. Diabetologia. 2018;16(S1):S391.
15.
go back to reference Xatzipsalti M, Mentesidou L, Kourti A, et al. Flash glucose monitoring system improves glycemic control. Pediatr Diabetes. 2017;18(Suppl. 25):78. Xatzipsalti M, Mentesidou L, Kourti A, et al. Flash glucose monitoring system improves glycemic control. Pediatr Diabetes. 2017;18(Suppl. 25):78.
16.
go back to reference Reddy M, Jugnee N, El Laboudi A, et al. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycaemia. Diabetes Med. 2018;35:483–90.CrossRef Reddy M, Jugnee N, El Laboudi A, et al. A randomized controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with type 1 diabetes and impaired awareness of hypoglycaemia. Diabetes Med. 2018;35:483–90.CrossRef
17.
go back to reference Moreno-Fernandez J, Pazos-Couselo M, González-Rodriguez M, et al. Clinical value of flash glucose monitoring in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. Endocrinol Diabetes Nutr. 2018;65:556–63.CrossRef Moreno-Fernandez J, Pazos-Couselo M, González-Rodriguez M, et al. Clinical value of flash glucose monitoring in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. Endocrinol Diabetes Nutr. 2018;65:556–63.CrossRef
18.
go back to reference Helm N, De ML, Forsman S, et al. Flash glucose monitoring improves perception and frequency of glucose monitoring leading to improved glucose control. Pediatr Diabetes. 2016;17:115. Helm N, De ML, Forsman S, et al. Flash glucose monitoring improves perception and frequency of glucose monitoring leading to improved glucose control. Pediatr Diabetes. 2016;17:115.
19.
go back to reference Messaaoui A, Tentoutasse S, Crenier L. Flash glucose monitoring in children–one-year experience. Diabetes. 2016;67(S1):946. Messaaoui A, Tentoutasse S, Crenier L. Flash glucose monitoring in children–one-year experience. Diabetes. 2016;67(S1):946.
20.
go back to reference Wijnands A, Gys I, Bevilacqua E, et al. The FreeStyle flash glucose monitoring system has limited effect on the metabolic control of children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2017;18(Suppl. 25):38. Wijnands A, Gys I, Bevilacqua E, et al. The FreeStyle flash glucose monitoring system has limited effect on the metabolic control of children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes. 2017;18(Suppl. 25):38.
22.
go back to reference Walton-Betancourth S, Amin R. A clinic-based study of the impact of flash glucose sensing technology on glycaemic control and self-monitoring of blood glucose in children and young people with type 1 diabetes. Pediatr Diabetes. 2017;18(Suppl. 25):47. Walton-Betancourth S, Amin R. A clinic-based study of the impact of flash glucose sensing technology on glycaemic control and self-monitoring of blood glucose in children and young people with type 1 diabetes. Pediatr Diabetes. 2017;18(Suppl. 25):47.
23.
go back to reference Dover AR, Stimson RH, Zammitt NN, Gibb FW. Flash glucose monitoring improves outcomes in a type 1 diabetes clinic. J Diabetes Sci Technol. 2017;11(2):442–3.CrossRef Dover AR, Stimson RH, Zammitt NN, Gibb FW. Flash glucose monitoring improves outcomes in a type 1 diabetes clinic. J Diabetes Sci Technol. 2017;11(2):442–3.CrossRef
24.
go back to reference Bacon S, O’Dwyer B, Chambers C, et al. The performance and technical usability of a flash glucometer monitoring system. Irish J Med Sci. 2017;186(9):S357. Bacon S, O’Dwyer B, Chambers C, et al. The performance and technical usability of a flash glucometer monitoring system. Irish J Med Sci. 2017;186(9):S357.
25.
go back to reference Dørflinger GH, Østergaard JA, Fisker S, et al. The effect of flash glucose monitoring on glycemic control in patients with type 1 diabetes. Diabetes. 2018;67(S1):942.CrossRef Dørflinger GH, Østergaard JA, Fisker S, et al. The effect of flash glucose monitoring on glycemic control in patients with type 1 diabetes. Diabetes. 2018;67(S1):942.CrossRef
26.
go back to reference Pintus D, Ng SM. FreeStyle Libre Flash glucose monitoring (Flash GM) system improves glycaemic control and patient quality of life measures in children with type 1 diabetes with appropriate provision of Flash GM education and support by healthcare professionals. Pediatr Diabetes. 2017;18(S25):eP004. Pintus D, Ng SM. FreeStyle Libre Flash glucose monitoring (Flash GM) system improves glycaemic control and patient quality of life measures in children with type 1 diabetes with appropriate provision of Flash GM education and support by healthcare professionals. Pediatr Diabetes. 2017;18(S25):eP004.
27.
go back to reference Karlsson E. HbA1c after one year of use of flash glucose monitoring in patients with type 1 diabetes. Thesis, University of Orebero, Sweden. Karlsson E. HbA1c after one year of use of flash glucose monitoring in patients with type 1 diabetes. Thesis, University of Orebero, Sweden.
28.
go back to reference Al Hayek A, Asirvatham RA, Al Dawish M. Evaluation of FreeStyle Libre flash glucose monitoring system on glycemic control, health-related quality of life, and fear of hypoglycemia in patients with type 1 diabetes. Clin Med Insights Endocrinol Diabetes. 2017;10:1–6. Al Hayek A, Asirvatham RA, Al Dawish M. Evaluation of FreeStyle Libre flash glucose monitoring system on glycemic control, health-related quality of life, and fear of hypoglycemia in patients with type 1 diabetes. Clin Med Insights Endocrinol Diabetes. 2017;10:1–6.
30.
go back to reference Abdalaziz A, Lan K, Bilous M, et al. Flash glucose monitoring (FGM) in people with type 1 diabetes: single centre-real-world experience. Diabetes Med. 2018;35(S1):168. Abdalaziz A, Lan K, Bilous M, et al. Flash glucose monitoring (FGM) in people with type 1 diabetes: single centre-real-world experience. Diabetes Med. 2018;35(S1):168.
31.
go back to reference Yaron M, Roitman E, Aharon-Hananel G, et al. Intervention of the flash glucose sensing technology on glycemic control and treatment satisfaction in patients with type 2 diabetes treated intensively using insulin: a randomized controlled trial. Diabetes. 2018;67(S1):908.CrossRef Yaron M, Roitman E, Aharon-Hananel G, et al. Intervention of the flash glucose sensing technology on glycemic control and treatment satisfaction in patients with type 2 diabetes treated intensively using insulin: a randomized controlled trial. Diabetes. 2018;67(S1):908.CrossRef
32.
go back to reference Weiss J, Cohen N, Zajac JD, et al. Flash glucose monitoring—using technology to improve outcomes for patients with diabetes. Aust J Rural Health. 2018;26:453–4.CrossRef Weiss J, Cohen N, Zajac JD, et al. Flash glucose monitoring—using technology to improve outcomes for patients with diabetes. Aust J Rural Health. 2018;26:453–4.CrossRef
33.
go back to reference Löndahl M, Filipsson K, Lindholm E, et al. Effect of flash glucose monitoring on metabolic control and self-esteem treatment satisfaction in people with T1DM. Diabetes Technol Ther. 2017;19(S1):A-81. Löndahl M, Filipsson K, Lindholm E, et al. Effect of flash glucose monitoring on metabolic control and self-esteem treatment satisfaction in people with T1DM. Diabetes Technol Ther. 2017;19(S1):A-81.
34.
go back to reference Landau Z, Abiri S, Gruber N, et al. Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: aWeSoME study group real-life observational experience. Acta Diabetol. 2018;55:1303–10.CrossRef Landau Z, Abiri S, Gruber N, et al. Use of flash glucose-sensing technology (FreeStyle Libre) in youth with type 1 diabetes: aWeSoME study group real-life observational experience. Acta Diabetol. 2018;55:1303–10.CrossRef
35.
go back to reference Ish-Shalom M, Wainstein J, Raz I, et al. Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J Diabetes Sci Technol. 2016;5:1572–83. Ish-Shalom M, Wainstein J, Raz I, et al. Improvement in glucose control in difficult-to-control patients with diabetes using a novel flash glucose monitoring device. J Diabetes Sci Technol. 2016;5:1572–83.
36.
go back to reference Holcombe A, Karunakaran V, Streeting J, et al. Trial of FreeStyle Libre in a local service: impact on diabetes outcomes. Diabetes Med. 2017;34(S1):160. Holcombe A, Karunakaran V, Streeting J, et al. Trial of FreeStyle Libre in a local service: impact on diabetes outcomes. Diabetes Med. 2017;34(S1):160.
37.
go back to reference Tirelli E, Frontino G, Favalli V, et al. Flash glucose monitoring in noncompliant children and adolescents with type 1 diabetes. Diabetes Technol Ther. 2017;19(S1):A-83. Tirelli E, Frontino G, Favalli V, et al. Flash glucose monitoring in noncompliant children and adolescents with type 1 diabetes. Diabetes Technol Ther. 2017;19(S1):A-83.
38.
go back to reference Hey C, Alkharaiji M, Anyanwagu U, et al. Impact of FreeStyle Libre on glycaemic control, frequency of glucose monitoring and treatment satisfaction. Diabetes Med. 2018;35(Supplement 1):195. Hey C, Alkharaiji M, Anyanwagu U, et al. Impact of FreeStyle Libre on glycaemic control, frequency of glucose monitoring and treatment satisfaction. Diabetes Med. 2018;35(Supplement 1):195.
39.
go back to reference Mitchell K, McDougall C. Trial of FreeStyle Libre flash glucose monitoring (FGM) in patients with poorly controlled type 1 diabetes. Diabetes Med. 2018;35(S1):160. Mitchell K, McDougall C. Trial of FreeStyle Libre flash glucose monitoring (FGM) in patients with poorly controlled type 1 diabetes. Diabetes Med. 2018;35(S1):160.
40.
go back to reference Higgins JPT, Thompson SG, Deeks J, et al. Measuring inconsistency in meta-analysis. BMJ. 2003;327:557–60.CrossRef Higgins JPT, Thompson SG, Deeks J, et al. Measuring inconsistency in meta-analysis. BMJ. 2003;327:557–60.CrossRef
41.
go back to reference Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted. Stat Med. 2002;21:1559–73.CrossRef Thompson SG, Higgins JPT. How should meta-regression analyses be undertaken and interpreted. Stat Med. 2002;21:1559–73.CrossRef
42.
go back to reference Sheu C-F, Suzuki S. Meta-analysis using linear mixed models. Behav Res Methods Instrum Comput. 2001;33:102–11.CrossRef Sheu C-F, Suzuki S. Meta-analysis using linear mixed models. Behav Res Methods Instrum Comput. 2001;33:102–11.CrossRef
Metadata
Title
The Impact of Flash Glucose Monitoring on Glycaemic Control as Measured by HbA1c: A Meta-analysis of Clinical Trials and Real-World Observational Studies
Authors
Mark Evans
Zoë Welsh
Sara Ells
Alexander Seibold
Publication date
01-01-2020
Publisher
Springer Healthcare
Published in
Diabetes Therapy / Issue 1/2020
Print ISSN: 1869-6953
Electronic ISSN: 1869-6961
DOI
https://doi.org/10.1007/s13300-019-00720-0

Other articles of this Issue 1/2020

Diabetes Therapy 1/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.